Marcia S. Brose, MD, PhD

Articles

Exploring Real-World Evidence Presented at ATA 2023

April 26th 2024

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Determining Which DTC Patients May Benefit from Systemic Therapy

April 26th 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Sequencing Throughout Multiple Lines of Therapy in RR DTC

June 5th 2023

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Optimizing Use of RET Inhibitors in Patients With RR DTC

May 29th 2023

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 3: Treating RR DTC With an Identified RET Fusion

May 29th 2023

Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.

Practical Considerations for Utilizing Second-Line Therapy in RR DTC

May 22nd 2023

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

Clinical Data Behind Second-Line Therapy in RR DTC

May 22nd 2023

A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 2: Second-Line Management of RR DTC With Cabozantinib

May 15th 2023

Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.

RR DTC: Managing Adverse Events With Dose Reductions or Holds

May 15th 2023

Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.

Quality of Life and Real-World Data in Patients With RR DTC

May 8th 2023

Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.

Overview of Available Treatment Options for RR DTC

May 8th 2023

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

RR DTC: Active Surveillance vs Initiating Systemic Therapy

May 1st 2023

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

Defining Radioiodine-Refractory Differentiated Thyroid Cancer

May 1st 2023

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

Practical Considerations for Managing RR DTC With Systemic Therapy

April 24th 2023

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

April 24th 2023

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Patient Profile 1: Lenvatinib in the Treatment of RAI-Refractory DTC

April 15th 2022

Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.

Patient Profile 1: Radioiodine-Refractory Differentiated Thyroid Cancer

April 15th 2022

Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.

Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC

February 13th 2015

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.

Dr. Brose Discusses Lenvatinib and Sorafenib in Differentiated Thyroid Cancer

November 2nd 2014

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.

Dr. Brose on the FACT2 Study and the Treatment of ATC

January 24th 2014

Marcia S. Brose, MD, PhD, from the University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.